Matthew Brown
About Matthew Brown
Matthew Brown is the Vice President and Head of Biopharma Project Management at Bristol Myers Squibb in New Jersey, United States, with extensive experience in project and portfolio management.
Company
Matthew Brown currently works at Bristol Myers Squibb in New Jersey, United States. He has been associated with the company since 1997 and has held various positions of increasing responsibility over the years. This extensive tenure underscores his commitment to the biopharma sector and his deep understanding of the company's operations.
Title
Matthew Brown serves as the Vice President and Head of Biopharma Project Management at Bristol Myers Squibb. In this role, he leads the Enterprise Governance Management, focusing on agile decision-making at the C-suite level. His leadership ensures that project and portfolio management is seamlessly integrated across enterprise divisions.
Education and Expertise
Matthew Brown holds a Bachelor of Science in Chemical Engineering from Cornell University. He furthered his education at the University of Pennsylvania, where he earned a Doctor of Philosophy in Chemical Engineering and Philosophy. His academic background provides a strong foundation for his extensive career in chemical engineering and biopharma project management.
Background
Matthew Brown has built a robust career in the biopharma and chemical engineering industries. He spent five years at American Cyanamid as a Process Development Engineer before joining Bristol Myers Squibb in 1997 as a Senior Research Investigator. Over the years, he advanced through various roles such as Research Manager, Associate Director, Director, Executive Director, and multiple Vice President-level positions.
Achievements
Matthew Brown has extensive experience managing complex biopharma projects and integrating project and portfolio management across enterprise divisions. His leadership in Enterprise Governance Management at Bristol Myers Squibb facilitates agile decision-making at the highest levels of the organization. His long-term contributions have helped position the company as a leader in the biopharma industry.